Posted by Michael Wonder on 20 Sep 2021
FDA clears first technology to distinguish between bacterial and viral infections using the body’s immune response – the MeMed BV test and MeMed key platform
20 September 2021 - MeMed BV is a first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes.
MeMed today announces that the U.S. FDA has granted 510(k) clearance for use of the MeMed BV test on the point-of-need platform MeMed Key to help healthcare providers distinguish between bacterial and viral infections.
The technology has been cleared for both children and adults.
